Replies to post #119 on Optimer Pharmaceuticals, Inc. (OPTR)

[kris_kade]

This stock has $20 written all over it. The findings from the journal adds more to the case that Difimicin will eat into Vanco's market share quickly. Treatment of C-Diff is a huge market and why would anyone prescribe vancomycin when Difimicin is so effective on cutting down the relapse rates as much as 45% ?